CSL Limited ( ASX:CSL ) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to ...

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...

This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity? The post What are brokers saying about ...